Therapeutic Drug Monitoring of Venlafaxine and Impact of Age, Gender, BMI, and Diagnosis
, , , , , , e
18 nov 2020
INFORMAZIONI SU QUESTO ARTICOLO
Categoria dell'articolo: Original Paper
Pubblicato online: 18 nov 2020
Pagine: 33 - 37
Ricevuto: 28 feb 2020
Accettato: 24 giu 2020
DOI: https://doi.org/10.2478/afpuc-2020-0005
Parole chiave
© 2019 Krivosova M. et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Medians of plasma concentrations (VEN and ODV; ODV+VEN) and metabolite to parent drug ratios (ODV/VEN) in patients treated with venlafaxine at the single daily dose of 300 mg (F32 – single episode of MDD; F33 – recurrent episode of MDD)
| Patients | VEN [ng/mL] | ODV [ng/mL] | ODV/VEN | ODV+VEN [ng/mL] | |
|---|---|---|---|---|---|
| Females | 15 | 255 | 370 | 1.85 | 693 |
| Males | 10 | 148 | 261 | 1.75 | 389 |
| Age < 65 | 21 | 132 | 304 | 1.92 | 417 |
| Age ≥ 65 | 4 | 345 | 511 | 1.55 | 859 |
| F32 | 7 | 128 | 280 | 2.00 | 435 |
| F33 | 18 | 198 | 356 | 1.74 | 553 |
Medians of dose-corrected plasma concentrations (DCC) of venlafaxine active moiety (F32 – single episode of MDD; F33 – recurrent episode of MDD)
| Patients | DCC [ng/mL/mg] | |
|---|---|---|
| Females | 16 | 2.07 |
| Males | 12 | 1.30 |
| Age < 65 | 24 | 1.39 |
| Age ≥ 65 | 4 | 2.86 |
| F32 | 8 | 1.46 |
| F33 | 20 | 1.61 |